AU2014362391B2 - Substituted nicotinamide derivatives as kinase inhibitors - Google Patents

Substituted nicotinamide derivatives as kinase inhibitors Download PDF

Info

Publication number
AU2014362391B2
AU2014362391B2 AU2014362391A AU2014362391A AU2014362391B2 AU 2014362391 B2 AU2014362391 B2 AU 2014362391B2 AU 2014362391 A AU2014362391 A AU 2014362391A AU 2014362391 A AU2014362391 A AU 2014362391A AU 2014362391 B2 AU2014362391 B2 AU 2014362391B2
Authority
AU
Australia
Prior art keywords
amino
phenyl
ethynyl
carbonyl
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2014362391A
Other languages
English (en)
Other versions
AU2014362391A1 (en
Inventor
Sougato Boral
Thomas Malone
Michael Robinson
Jie Shen
Shimiao Wang
Julie Wurster
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Allergan Inc
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of AU2014362391A1 publication Critical patent/AU2014362391A1/en
Application granted granted Critical
Publication of AU2014362391B2 publication Critical patent/AU2014362391B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D411/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms
    • C07D411/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D411/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D411/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms
    • C07D411/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
AU2014362391A 2013-12-12 2014-12-10 Substituted nicotinamide derivatives as kinase inhibitors Ceased AU2014362391B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361915186P 2013-12-12 2013-12-12
US201361915209P 2013-12-12 2013-12-12
US61/915,186 2013-12-12
US61/915,209 2013-12-12
PCT/US2014/069601 WO2015089220A1 (en) 2013-12-12 2014-12-10 Substituted nicotinamide derivatives as kinase inhibitors

Publications (2)

Publication Number Publication Date
AU2014362391A1 AU2014362391A1 (en) 2016-06-16
AU2014362391B2 true AU2014362391B2 (en) 2019-04-04

Family

ID=52118045

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2014362391A Ceased AU2014362391B2 (en) 2013-12-12 2014-12-10 Substituted nicotinamide derivatives as kinase inhibitors

Country Status (8)

Country Link
US (2) US20150166518A1 (enExample)
EP (1) EP3080084B1 (enExample)
JP (1) JP6531100B2 (enExample)
CN (1) CN105814021B (enExample)
AU (1) AU2014362391B2 (enExample)
BR (1) BR112016013539A2 (enExample)
CA (1) CA2932831A1 (enExample)
WO (1) WO2015089220A1 (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10046649B2 (en) 2012-06-28 2018-08-14 Midtronics, Inc. Hybrid and electric vehicle battery pack maintenance device
US20110300416A1 (en) 2010-06-03 2011-12-08 Bertness Kevin I Battery pack maintenance for electric vehicle
US11740294B2 (en) 2010-06-03 2023-08-29 Midtronics, Inc. High use battery pack maintenance
DE112012004706T5 (de) 2011-11-10 2014-08-21 Midtronics, Inc. Batteriepack-Testvorrichtung
US11325479B2 (en) 2012-06-28 2022-05-10 Midtronics, Inc. Hybrid and electric vehicle battery maintenance device
US10843574B2 (en) 2013-12-12 2020-11-24 Midtronics, Inc. Calibration and programming of in-vehicle battery sensors
US10473555B2 (en) 2014-07-14 2019-11-12 Midtronics, Inc. Automotive maintenance system
US10317468B2 (en) 2015-01-26 2019-06-11 Midtronics, Inc. Alternator tester
US10608353B2 (en) 2016-06-28 2020-03-31 Midtronics, Inc. Battery clamp
US12320857B2 (en) 2016-10-25 2025-06-03 Midtronics, Inc. Electrical load for electronic battery tester and electronic battery tester including such electrical load
US11054480B2 (en) 2016-10-25 2021-07-06 Midtronics, Inc. Electrical load for electronic battery tester and electronic battery tester including such electrical load
CN108456163A (zh) 2017-02-20 2018-08-28 中国科学院上海药物研究所 含邻氨基杂芳环炔基的化合物及其制备方法和用途
US11513160B2 (en) 2018-11-29 2022-11-29 Midtronics, Inc. Vehicle battery maintenance device
CN111662227B (zh) * 2019-03-06 2022-07-05 中国科学院上海药物研究所 邻氨基吡啶炔类化合物及其制备方法和用途
US11566972B2 (en) 2019-07-31 2023-01-31 Midtronics, Inc. Tire tread gauge using visual indicator
US11545839B2 (en) 2019-11-05 2023-01-03 Midtronics, Inc. System for charging a series of connected batteries
US11668779B2 (en) 2019-11-11 2023-06-06 Midtronics, Inc. Hybrid and electric vehicle battery pack maintenance device
US11474153B2 (en) 2019-11-12 2022-10-18 Midtronics, Inc. Battery pack maintenance system
US11973202B2 (en) 2019-12-31 2024-04-30 Midtronics, Inc. Intelligent module interface for battery maintenance device
DE102020216599A1 (de) 2019-12-31 2021-07-01 Midtronics, Inc. Intelligente Modulschnittstelle für eine Batteriewartungsvorrichtung
US11486930B2 (en) 2020-01-23 2022-11-01 Midtronics, Inc. Electronic battery tester with battery clamp storage holsters
US12330513B2 (en) 2022-02-14 2025-06-17 Midtronics, Inc. Battery maintenance device with high voltage connector
US12392833B2 (en) 2022-05-09 2025-08-19 Midtronics, Inc. Electronic battery tester

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013062843A1 (en) * 2011-10-20 2013-05-02 Allergan, Inc. Pyridine- sulfoximines as tyrosine kinase inhibitors

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7915443B2 (en) * 2006-11-16 2011-03-29 Allergan, Inc. Sulfoximines as kinase inhibitors

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013062843A1 (en) * 2011-10-20 2013-05-02 Allergan, Inc. Pyridine- sulfoximines as tyrosine kinase inhibitors

Also Published As

Publication number Publication date
JP6531100B2 (ja) 2019-06-12
WO2015089220A1 (en) 2015-06-18
CA2932831A1 (en) 2015-06-18
BR112016013539A2 (pt) 2020-10-27
US20160194311A1 (en) 2016-07-07
CN105814021A (zh) 2016-07-27
CN105814021B (zh) 2020-03-13
US20150166518A1 (en) 2015-06-18
AU2014362391A1 (en) 2016-06-16
JP2016539995A (ja) 2016-12-22
US9567324B2 (en) 2017-02-14
EP3080084B1 (en) 2018-06-13
EP3080084A1 (en) 2016-10-19

Similar Documents

Publication Publication Date Title
AU2014362391B2 (en) Substituted nicotinamide derivatives as kinase inhibitors
CA2946519C (en) Isoindoline-1-one derivatives as cholinergic muscarinic m1 receptor positive alloesteric modulator activity for the treatment of alzheimers disease
JP5799479B2 (ja) Ｒｈｏキナーゼインヒビター
EP3156397B1 (en) Nitrogen-containing heterocyclic compound
WO2019027054A1 (en) HETEROCYCLIC COMPOUND
CN107922403A (zh) 作为胆碱能毒蕈碱m1受体的调节剂的2,3‑二氢‑4h‑1,3‑苯并噁嗪‑4‑酮衍生物
EP3428150B1 (en) Aromatic ring compound having a cholinergic muscarine m1 receptor positive allosteric modulator activity
AU2014362381B2 (en) Substituted dialkyl(oxido)-lambda4-sulfanylidene nicotinamide derivatives as kinase inhibitors
ES2623652T3 (es) Derivados de 3-fenil-5-ureidoisotiazol-4-carboximida y 3-amino-5-fenilisotiazol como inhibidores de cinasa
HK40043779A (en) Substituted dialkyl(oxido)-lambda4-sulfanylidene nicotinamide derivatives as kinase inhibitors
WO2013177053A1 (en) Pyrimidino [1, 2 -c] quinazolinone derivatives as tyrosine kinases inhibitors
HK1227390A1 (en) Substituted nicotinamide derivatives as kinase inhibitors
CA2899300A1 (en) N-acylpyrrolidine ether derivatives
HK1227390B (zh) 作为激酶抑制剂的取代的烟酰胺衍生物
HK1228396A1 (en) Substituted dialkyl(oxido)-λ4-sulfanylidene nicotinamide derivatives as kinase inhibitors

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired